Co-Chairs

Savaria B. Harris

Senior Counsel, Regulatory Law
Johnson & Johnson


Paul Kaufman

Vice President, Office of Legal Affairs
Northwell Health

For fiscal year 2020, the DOJ reported that over 80% of all False Claims Act recoveries came from the life sciences and healthcare industries – amounting to nearly $1.9 billion.

There is a sustained and aggressive use of the False Claims Act by the government and Qui Tam relators alike.  By all accounts, the trend for government initiated FCA actions is continuing to climb, leaving the life sciences and healthcare industries pondering:

  • Will the FCA enforcement increase under the Biden Administration?
  • What can we expect for Fiscal ‘21?
  • Where will government enforcement priorities lie?
  • What can you do now to prepare for the next wave of FCA enforcement?

 Although they are companion industries, life sciences and healthcare often operate in individual silos. However, the stakeholders often work hand in glove, and the unwritten lessons to be learned from each industry can foster collaboration and commitment to compliance.

This dual industry-tailored summit will address the underlying controversies and challenges posed by this latest FCA activity.  The forum will feature key stakeholders from the life sciences and healthcare communities, including senior government officials, industry executives and leading private practitioners for a meeting of the minds between the life sciences and healthcare.  

Join us for in-depth discussion and analyses of the latest guidance, initiatives and enforcement statistics impacting the life sciences and healthcare industries as we analyze what each group can learn from the other in this latest round of FCA activity.

Benefits
  • BENEFIT from the insights of the ‘who’s who’ of the FCA community
  • DEVELOP compliance strategies to reduce risk and avoid penalties
  • ANALYZE the latest rulings, settlements and developments impacting the life sciences and healthcare industries
  • LEARN firsthand from senior government officials on how they evaluate cases
Featuring a Special Pandemic Recovery Update with

Brian D. Miller

Special Inspector General for Pandemic Recovery (SIGPR)
U.S. Department of The Treasury

Hear Directly from Government Enforcers

A. Brendan Stewart

Assistant Chief
Fraud Section, Criminal Division

U.S. Department of Justice

Joseph A. Marutollo

Assistant United States Attorney
Acting Chief, Civil Division
United States Attorney’s Office

Eastern District of New York

Rachael A. Honig

Acting U.S. Attorney
District of New Jersey

Jolie Apicella

Chief, Civil Health Care Fraud
United States Attorney’s Office

Eastern District of New York

Charlene Keller Fullmer

Deputy Civil Affirmative Chief
U.S. Attorney’s Office

Eastern District of Pennsylvania

Who Should Attend
  • General Counsel
  • Chief Legal Counsel
  • Chief Compliance Officer
  • Assistant General Counsel
  • In-House Counsel
  • Litigators
  • Outside Counsel specializing in:
    • False Claims Act
    • Fraud and Abuse
    • Litigation
    • Corporate Compliance
    • White Collar Crime
    • Healthcare
    • Life Sciences

Related Conferences